financetom
Business
financetom
/
Business
/
Klaviyo Early 2025 Projections Show Limited Operating Margins, Morgan Stanley Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Klaviyo Early 2025 Projections Show Limited Operating Margins, Morgan Stanley Says
Nov 9, 2024 12:27 PM

12:51 PM EST, 11/07/2024 (MT Newswires) -- Klaviyo's ( KVYO ) year-over-year revenue growth in Q3 places it in "rare air" among software companies, but early look into 2025 dynamics show that ongoing investments are limiting operating margins, Morgan Stanley said in a note Thursday.

The analysts said that despite the company's ability to sustain 34% year-over-year revenue growth as it approaches a billion-dollar revenue run rate, investor sentiment has been dampened after Q3 due to a few factors. This quarter's revenue beat was smaller at 4%, compared to Q2 at 5%, net revenue retention, NRR, dropped 2 percentage points to 110%, and early full-year 2025 guidance suggests continued NRR decline, which could slow revenue growth further from the 27% to 28% guidance for Q4.

"Given this track record, turning the dial further on investments would appear to be the correct strategic decision, despite the near-term pressure on operating margins. Bottom line, with Klaviyo ( KVYO ) proving out an ability to well sustain top-line growth despite the uneven small and medium-sized businesses backdrop and well expand up-market, investments behind that growth are warranted," the analysts said.

The analysts added that the company's management plans to continue investing into 2025, given the success of its marketing and product efforts this year, and as a result, it expects operating margins in full-year 2025 to stay similar to those in 2024.

Morgan Stanley raised Klaviyo's ( KVYO ) price target to $38 from $32, while keeping its equalweight rating.

Shares of the software firm fell past 15% in recent trading.

Price: 34.03, Change: -6.33, Percent Change: -15.68

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Once a beacon of stability, Vietnam to name third president in a year
Once a beacon of stability, Vietnam to name third president in a year
Mar 22, 2024
HANOI, March 22 (Reuters) - Communist-ruled Vietnam is seeking its third president in little more than a year after the resignation of Vo Van Thuong, who was only elected last year after the sudden dismissal of his predecessor. With accumulated foreign direct investment higher than its gross domestic product, Vietnam's stability is crucial to multinationals with large operations in the...
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Cathie Wood's ARK Invest scoops up nearly 10,000 Reddit shares in debut
Mar 22, 2024
(Reuters) - Popular investor Cathie Wood's ARK Invest bought nearly 10,000 shares of Reddit ( RDDT ) in the social media platform's strong market debut on Thursday, an email from the asset manager showed. A total of 9,982 shares of the loss-making company was added to ARK Next Generation Internet ETF ( ARKW ) and ARK Fintech Innovation ETF (...
Japan's union group Rengo announces biggest wage hikes on record
Japan's union group Rengo announces biggest wage hikes on record
Mar 22, 2024
TOKYO (Reuters) -Japanese firms have agreed to raise pay by 5.25% this year, the biggest rise under comparable data since 2013, the country's largest union group Rengo confirmed on Friday. The results of the closely-watched wage negotiations are announced in several stages, in which the blue-chip firms are first to wrap up their talks in mid-March. The second announcement on...
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Hutchmed Begins Registration Stage for Phase 2/3 Trial of Investigational Autoimmune Disorder Drug
Mar 22, 2024
05:04 AM EDT, 03/22/2024 (MT Newswires) -- Hutchmed ( HCM ) said late Thursday it has started the registration stage for a phase 2/3 clinical trial of investigational drug sovleplenib for adult patients with warm antibody autoimmune hemolytic anemia in China. The move follows positive data from the proof-of-concept phase 2 stage of the trial and a consultation with the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved